Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA pharmacogenomic study of pemetrexed plus cisplatin as first-line treatment in advanced non-squamous non-small cell lung cancer
2009-011327-31Phase 2Terminated
- Sponsor
- Fundación GECP
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and cisplatin in Non-small cell lung cancer (NS-NSCLC), sponsored by Fundación GECP. Primary endpoint: Objective response rate. Started Jun 2009; status: terminated.
02
Drugs
pemetrexedcisplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2009-011327-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011327-31.